durvalumab,ab154,domvanalimab
astrazeneca,otsuka,arcus biosciences,gilead
['pacific-8', 'nsclc', 'lcsm,(-blcsm)', 'pacific,(-pacifica),(-pacific 6),(-pacific6),(-pacific-6),(-pacific-a),(-pacific a)', 'domvana', 'durva', 'sclc', 'ab154']
tps8609: phase 3 trial of durvalumab combined with domvanalimab (ab154, anti-tigit) following concurrent chemoradiotherapy in patients with unresectable stage iii nsclc (pacific-8, nct05211895) by . #asco23 #lcsm 
Medical Oncologist, National Cancer Center Hospital, Lung Cancer Study Group @JCOG_official, Educational Committee @JSMO_official, @JLCS_OFFICIAL, @IASLC